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ABSTRACT
Objectives: Vertigo and dizziness, which are major symp-
toms of diseases affecting the vestibular system, drastically
impair patients’ health-related quality of life (QoL). Patient’s
perspectives are thus essential to symptom assessment. We
sought to make a critical review of published questionnaires
measuring vertigo or dizziness, and/or their impact on QoL.
Methods: Twenty-nine articles reporting the validation or
use in clinical trials of vertigo- or dizziness-speciﬁc question-
naires were identiﬁed over the 1991–2004 period, and
reviewed using a methodological and a Patient-Reported
Outcomes speciﬁc checklist. Questionnaires were classiﬁed
into three categories according to content: QoL (or handi-
cap), mixed (assessing both symptoms and QoL), and
symptom questionnaires.
Results: Four QoL, three mixed questionnaires, two symp-
toms, and one Meniere’s disease-speciﬁc questionnaire were
identiﬁed. QoL questionnaire validation was usually not
complete. The structural validity of the Dizziness Handicap
Inventory is not established, although this questionnaire is
considered to be the reference questionnaire in the QoL
domain. Moreover, QoL questionnaires were not very spe-
ciﬁc to vertigo or dizziness. Similarly, the Vertigo Handicap
Questionnaire appeared to have the most pertinent content,
but its validation remains to be completed. Mixed question-
naires have the same imperfections. The Vertigo, Dizziness,
Imbalance (VDI) Questionnaire had the best validation score
from the checklist, but its responsiveness appears to be weak.
Regarding symptom questionnaires, the European Evalua-
tion of Vertigo questionnaire evaluated the ﬁve major symp-
toms of vestibular syndrome satisfactorily.
Conclusion: The present literature review failed to ﬁnd any
relevant and validated questionnaire assessing the impact of
vertigo or dizziness on QoL.
Keywords: dizziness, patient-reported outcomes, quality of
life, vertigo.
Introduction
Vertigo and dizziness are major symptoms of diseases
affecting the vestibular system. They can be induced by
either chronic or transitory disorders, with unpredict-
able recurrence, making their clinical features variable.
Benign paroxystic vertigo (i.e., short acute episodes in
a context of normal functioning) is the most frequent
form. On the other hand, vestibular neuritis, Meniere’s
disease, and other forms of recurrent vertigo are char-
acterized by longer duration of symptoms (i.e., vertigo
followed by dizziness) with frequent, unpredictable
recurrence of variable intensity.
The subjective perception of vertigo and dizziness is
inﬂuenced by the patient’s personality, anxiety with
regard to unforeseeable recurrence, associated symp-
toms (neurovegetative, hearing disorder, etc.), and the
unpredictable evolution of the underlying disease. Sub-
jective perception is thus only poorly correlated with
objective assessment, by vestibular testing for example
[1–3]. Agreement between patient’s and physician’s
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symptom assessment has been reported to be moderate
for vertigo and other symptoms [4,5]. Because vertigo
and dizziness impair daily life, even during asymptom-
atic periods, mere symptom assessment is not sufﬁ-
cient: the patient may in fact be more worried by the
anticipation of the next unpredictable episode of
vertigo or dizziness than by the symptom itself [1,2].
This is also true for other conditions such as irritable
bowel syndrome or migraine [6,7].
In this context, the patient’s perspective appears to
be essential if all the aspects of vertigo and dizziness
are to be taken into account; hence, it would be useful
to have a relevant and valid questionnaire, ﬁlled in by
the patient, which could be used both in everyday
practice and for therapeutic strategy assessment. The
present study sought to inventory and describe pub-
lished questionnaires measuring vertigo and dizziness
and/or their impact on health-related quality of
life (QoL) and to make recommendations as to their
use.
Methods
Articles published in English or French were invento-
ried over the 1991–2000 period in the MEDLINE and
EMBASE databases, using the following key words:
“dizziness, vertigo, vestibular disorders, balance disor-
ders” and “scale, instrument, questionnaire, index,
quality of life, health status, well-being.” Of the 39
articles identiﬁed by this literature review, 29 were
selected by the organizing committee (Olivier Chas-
sany, Isabelle Mosnier, Didier Bouccara, Olivier Sterk-
ers) as reporting validation of vertigo- or dizziness-
speciﬁc questionnaires or their use in clinical trials.
Each of these 29 articles was reviewed by the orga-
nizing committee and by two or three members of the
working group. The working group (18 members) was
multidisciplinary, mainly comprising ear, nose, and
throat (ENT) specialists, but also physical therapist,
neurologists, pain specialists, and general practitioner.
Articles were reviewed using the ANAES (Agence
Nationale d’Accréditation et d’Evaluation en Santé)
general methodological checklist (http://www.
anaes.fr). Questionnaires were then classiﬁed accord-
ing to content, in three categories: symptom, QoL (or
handicap), and mixed questionnaires (assessing both
symptoms, and QoL or handicap). The face validity
(i.e., relevance of each item to vertigo and/or dizziness)
was considered for each questionnaire. The working
group was also asked to check whether the validation
study population was representative of the population
of patients suffering from vertigo or dizziness.
Each questionnaire validation report was reviewed
by one member of the organizing committee (Olivier
Chassany), using a Patient-Reported Outcomes
(PRO)-speciﬁc checklist derived from the European
Regulatory Issues on Quality of Life Assessment
Working Group (ERIQA) [8]. This checklist (Table 1)
has already been used in other reviews (i.e., asthma,
chronic obstructive pulmonary disease or irritable
bowel syndrome) [9,10]. It is based on 15 criteria, each
scored between 0 and 4, giving a total score of between
0 (poor validation) and 100 (good validation) after
transformation.
At the end of this systematic appraisal, a further
literature search was conducted over the 2001–2004
period. But no publication relating to validation of any
new speciﬁc questionnaire for vertigo and/or dizziness
was identiﬁed.
Results
Table 2 presents the 10 questionnaires identiﬁed in the
29 articles: four QoL or handicap [1,11–25], three
mixed [5,26,27], and two symptomatic [2,28–33]
questionnaires were identiﬁed plus one Meniere’s
disease-speciﬁc questionnaire [34,35]. Validation
scores obtained from the PRO-speciﬁc checklist
(Table 1) ranged between 36 and 77 (Fig. 1). An addi-
tional Meniere’s disease-speciﬁc questionnaire, from
the American Academy of Otolaryngology—Head and
Neck Surgery (AAO-HNS), was identiﬁed, but was not
assessed, because validation data were not available
Table 1 Checklist used to assess the validity of the
questionnaires
1. Item generation and conceptual model underlying the development
of the questionnaire. Level of patients’ input
2. Description and adequacy of the population involved in the
different steps of validation
3. Size of the population involved in the different steps of validation
4. Description of the questionnaire (number of items and dimensions)
5. Scaling (response options) and scoring
6. Period recall (period to which the answers must relate)
7. Item reduction process (may involve distribution of response
options, content validity, expert opinion, and psychometric analyses:
i.e., factor analysis)
8. Internal consistency (level of correlation of the items in a
dimension)*
9. Test–retest (stability of scores over time when patient’s condition
is considered stable)*
10. Content validity (items and response options are relevant and
comprehensive of the dimensions)
11. Structural validity (factor analysis or similar to support the
hypothesized scale structure: i.e., the combination of items into
dimensions)†
12. Discriminant validity (capacity of the questionnaire to discriminate
the patients according to certain characteristics, e.g., severity of the
disease)†
13. Convergent validity (correlations of the questionnaire with a scale
known as of reference or which is supposed to measure more or
less similar concepts)†
14. Predictive validity (future evolution of the disease can be predicted
by score changes of the questionnaire)†
15. Responsiveness (ability to detect changes)
*Internal consistency and test–retest measure questionnaire reliability.
†Structural, discriminant, and convergent validity are part of the construct validity,
which assesses the conformity with the conceptual model of the relationship between
items and dimensions.
Scores for each item ranged between 0 (bad) and 4 (good).A total score was then
computed to obtain a range from 0 (bad) to 100 (good).
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[36]. A description and critique of each identiﬁed
measure is provided below.
Quality of Life or Handicap Questionnaires (Table 3)
The Dizziness Handicap Inventory (DHI) is a 25-item
measure that evaluates the self-perceived deleterious
effect of vestibular syndrome in the patient’s daily life
[1]. Content analysis grouped the 25 items into three
dimensions: functional, emotional, and physical
aspects of dizziness and unsteadiness. Discriminant
validity was demonstrated by the good relationships
between number of dizziness episodes (i.e., <12, 12,
permanent dizziness) and DHI scores. Convergent
validity, studied in 67 patients identiﬁed on an ENT
specialist outpatient waiting list, was demonstrated by
the high correlation coefﬁcients between the total DHI
score and the eight dimensions of the generic question-
naire SF-36 [11].
The DHI from its frequent use could be regarded as
a reference questionnaire, because the questionnaire
items seem relevant to the context of the symptoms.
Nevertheless, the patients who have taken part in the
various validation studies are not fully representative
of the population with dizziness, because many
patients had a chronic pathology evolving for several
years. The construct validity of the DHI is question-
able, because only item–total correlation has been
studied. A factor (or similar) analysis would have been
necessary to check the hypothesized scale structure by
demonstrating that correlations between items from a
given dimension are stronger than with items from
other dimensions. Moreover, two studies call into
question the structure of the DHI [13,14]. A factor
analysis, involving 95 patients referred to a tertiary-
care vestibular disorders clinic, yielded three factors
comprising items different from those recommended
by Jacobson et al: “disability in activities of daily
living,” “phobic avoidance,” and “postural difﬁcul-
ties” [13]. Similarly, Perez et al. in a factor analysis on
data from 337 Spanish patients [14], found three
factors, different from those in the original publica-
tion: “vestibular disability,” “vestibular handicap,”
and “visio-vestibular disability.” Slight changes in
questionnaire structure are usual when questionnaires
are adapted to other countries; but one needs to be
sure that a forward–backward translation procedure is
used in producing other language versions of the DHI
to ensure that the concepts of the original English
version are conserved. These methodological issues in
the DHI are signiﬁcant, casting doubt on the validity of
the measure.
Lastly, the responsiveness of the DHI has been
studied on a very limited number of patients, or retro-
spectively, preventing any deﬁnitive conclusions [1,15–
18]. Two different short versions of the DHI have also
been published [19,20]. It remains unclear whether
these short versions are sufﬁciently responsive to be
used as assessment tools.
The Vestibular Disorders Activities of Daily Living
(VADL) scale assesses the impact of vestibular impair-
ment on everyday activities. The 28 items are grouped
into three dimensions: functional (self-care and
Table 2 Names of the 10 vertigo- and dizziness-speciﬁc questionnaires identiﬁed and selected from the literature review (1991–2000)
Classiﬁcation Abbreviation Name References
Handicap or quality of life DHI Dizziness Handicap Inventory [1,11–20]
VADL Vestibular Disorders of Daily Living Scale [21,22]
ABC Activities-speciﬁc Balance Conﬁdence [23,24]
VHQ Vertigo Handicap Questionnaire [25]
Mixed VDI Vertigo, Dizziness, Imbalance Questionnaire [26]
UCLA-DQ UCLA Dizziness Questionnaire [5]
DFI Dizzy Factor Inventory [27]
Symptomatic VSS Vertigo Symptom Scale [2,28–32]
EEV European Evaluation of Vertigo [33]
Meniere’s disease MD-POSI Meniere’s Disease Patients-Oriented Severity Index [34,35]
Mixed questionnaires assess both symptoms and their impact on quality of life. An additional Meniere’s disease-speciﬁc questionnaire, the American Academy of
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Figure 1 Quality of validation score for each of the questionnaires
assessing vertigo or dizziness, and/or its disabling consequences on quality
of life. Mixed questionnaires assess both symptoms and their impact on
quality of life. Scores assessed the quality of the validation of the ques-
tionnaires according to the 15 criteria listed in Table 1. They ranged
between 0 (poor validation) and 100 (good validation). ABC, Activities-
speciﬁc Balance Conﬁdence; DFI, Dizzy Factor Inventory; DHI, Dizziness
Handicap Inventory; EEV, European Evaluation of Vertigo; POSI, Patients-
Oriented Severity Index; UCLA-DQ, UCLA Dizziness Questionnaire;
VADL,Vestibular Disorders of Daily Living Scale; VDI, Vertigo, Dizziness,
Imbalance Questionnaire; VHQ, Vertigo Handicap Questionnaire; VSS,
Vertigo Symptom Scale.
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Table 3 Principal elements of validation of handicap or quality of life questionnaires
Questionnaire DHI VADL ABC VHQ
Author (year) Jacobson (1990) [1] Cohen (2000) [21] Powell (1995) [23] Yardley (1992) [25]
Items/dimensions 25/3 28/3 16/1 22/4
Item generation HHI for the elderly [3] and
patients’ interview (n = 63;
49 19 years; women:
60%). Patients from an
audiology department
ADL questionnaire [45] and




FES [37] and patients’
(n = 13, >65 years) and






106 patients referred for
vestibular tests
(48 16 years, women:
62%).Three groups of
patients: <12 episodes
within the previous year
(n = 39);12 episodes
(n = 51); or permanent
(n = 16)
93 patients referred for
vestibular rehabilitation
after diagnosis of peripheral
vestibular disorder: (a) with
CV > 3 months (n = 66,
55 17 years; women:
68%); (b) with posterior
canal BPPV (n = 27; 52
12 years; 74%) 28 patients
with unilateral BPPV
(content analysis of the ﬁnal
version)
60 subjects (age:
65–95 years, men: 72%).The
mobility (high or low) of
the subjects was evaluated
according to the need for
assistance in walking or not
84 patients (16–78 years;
women: 64%) referred for a
vertigo evolving for










and stair climbing (9 items).
Instrumental: home
management, productivity,




living that while requiring
some position change or
walking, would be safe and
nonhazardous to most
elderly persons
Handicap of restriction of
activity. Social anxieties.
Fears about vertigo. Severity
of vertigo attacks
Items scaling Yes/sometimes/no scored
0/2/4, respectively
10-point Likert verbal scale:
from 1 (independent) to 10
(too difﬁcult, no longer
perform)
0–100 response continuum 5-point Likert verbal scale,
from 0 (no handicap) to 4
(maximum handicap)






1–10 0 (no conﬁdence) to 100
(complete conﬁdence in
performing the task without









Total score: 0.97; 3
Dimensions: from 0.91 to
0.96
0.96 Total score: 0.93;
Dimensions: 0.75–0.82
Reproducibility
(test–retest): r = intraclass
coefﬁcient (except VHQ)





17 patients (2-h interval).







No signiﬁcant change (test
t, P > 0.05)




Analysis close to that of the
item- total correlation*
Factor analysis yielded 4
factors (dimensions)
Discriminant validity Discrimination of the
patients according to the




patients (P < 0.0001). No
difference between patients
with BPPV and CV. No
correlation between VADL





from r = 0.32 (P = 0.04) to
0.42 (P = 0.004) (Spearman)
ABC scores lower in
patients fallen the previous
year than not fallen
(P = 0.058).ABC scores
lower in patients with than
without reduced mobility:
38.3 vs. 80.9 (P < 0.001)
VHQ score impaired when
the rotatory vertigo is
recurrent instead of being
single (P < 0.03)
Convergent validity DHI vs. SF-36: r from 0.53
to 0.72 according to
dimensions (Spearman)
VADL vs. DHI: r = 0.66,
P < 0.001 (Spearman)
ABC vs. DHI: r = -0.64,
P < 0.0005;ABC vs. FES:
r = 0.84, P < 0.001
Not evaluated
Responsiveness Several retrospective
studies and/or with a weak
number of subjects. Score
values not presented
Not evaluated Not evaluated VHQ score decreased (test
t, P = 0.04) among 14
patients who improved
after 6 months
Total number of patients 769 252 131 84
*Study of the correlations of the items compared with the whole questionnaire; †Two subsequent and independent studies questioned the structure of the questionnaire, using
factor analysis [13,14].
ABC,Activities-speciﬁc Balance Conﬁdence questionnaire;ADL,Activities of Daily Living; BPPV, benign paroxysmal positional vertigo; CV, chronic vertigo; DHI, Dizziness Handicap
Inventory; FES, Falls Efﬁcacy Scale; HHI, Hearing Handicap Inventory; SF-36, generic quality of life questionnaire;VADL,Vestibular Disorders of Daily Living Scale;VHQ,Vertigo
Handicap Questionnaire.
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intimate activities), ambulation (walking and stair
climbing), and instrumental (home management and
leisure activities) [21]. The population included in the
validation study consisted of 93 patients referred for
vestibular rehabilitation after a diagnosis of peripheral
vestibular disorder had been made by an otolaryngolo-
gist or neurologist [21,22].
The content and wording of items on the VADL
do not seem very speciﬁc to vertigo. Reproducibility
has also not been measured adequately. The construct
validity of the VADL has not been veriﬁed using
factor analysis, but only by item–total correlations,
and correlations of items within their dimensions.
Convergent validity has been demonstrated by the
high correlation between the total VADL and total
DHI scores [22]. There is some evidence of discrimi-
nant validity, because VADL scores have been shown
to distinguish patients from controls (P < 0.0001)
[22], Nevertheless, the VADL did not discriminate
patients with benign paroxysmal positional vertigo
(BPPV) from patients with chronic vestibulopathy.
Likewise, there was no signiﬁcant correlation
between VADL total score and the intensity of
vertigo. There was only a moderate correlation
between frequency of vertigo, and total VADL score
and the “instrumental” dimension score [22]. Thus,
interpretation is far from straightforward, because
the discriminant capacity of the VADL with respect
to other clinical measures of vertigo is moderate or
nonexistent. A new questionnaire should show a
minimum of discriminant capacity according, for
example, to the severity of the disease. It is possible
that the VADL’s lack of discriminant capacity is
related to the absence of impairment in the validation
study population: mean score around 1 on a scale
from 1 (good) to 10 (bad).
The 16-item Activities-speciﬁc Balance Conﬁdence
(ABC) scale was developed to provide a more precise
description of elderly people’s everyday difﬁculties and
fear of falling [23]. An analysis close to that performed
in item–total correlation studies was made to measure
the link between each item and the scale as a whole.
The ABC score was able to discriminate patients
with and without a fall within the previous year
(P = 0.058). Likewise, the ABC score was lower in
patients with reduced mobility than without reduced
mobility (P < 0.001). A high correlation was found
between ABC and DHI scores in a study performed on
71 patients over 65 years of age [24].
The content and wording of the ABC questionnaire
is not speciﬁc to vertigo. It focuses on elderly subjects’
mobility. The strong correlation between the ABC and
the Falls Efﬁcacy Scale [37], from which the former
was generated, raises the question as to whether the
ABC provides any new or better information [23]. At
all events, it is unsuited for the study of vertigo and
balance disorders.
The Vertigo Handicap Questionnaire (VHQ)
includes 22 items reﬂecting the disabling consequences
of vertigo, including limitations of vertigo on physical
and everyday activities to its impacts on social life and
leisure [25]. Factor analysis yielded four factors,
explaining 63% of the variance. Item reduction,
mainly based on the level of correlation of the items
with the dimensions, reduced the number of items
from 46 to 22. Discriminant validity was assessed
using patients with episodic rotatory vertigo and
patients only having experienced a single episode.
Scores were worse in case of episodic vertigo
(P < 0.03). The responsiveness of the VHQ has been
studied only on a very limited number of patients [25].
In general, the VHQ appears to be one of the most
relevant and promising questionnaires for assessing the
impact of vertigo on QoL. Its psychometric properties,
however, need to be conﬁrmed with larger numbers of
patients [25,28].
Mixed Questionnaires (Table 4)
The 36-item Vertigo, Dizziness, Imbalance (VDI) ques-
tionnaire measures feelings of dizziness and unsteadi-
ness and their psychosocial consequences [26]. Item
reduction, based on content analysis and factor analy-
sis, reduced 175 initial items to 36. Items were empiri-
cally grouped into two dimensions—symptoms (VDI
symptoms) and QoL (VDI HRQoL)—on the basis of
content analysis. A factor analysis, however, was not
performed on all items but on these two empirical
dimensions, raising some doubt as to the construct
validity of the subscales. Scores on the two VDI dimen-
sions evolved similarly to a balance scale (functional
capacity to maintain balance while performing 14
movements required in everyday living) [38] and per-
ceived symptom severity scores (P < 0.001). Conver-
gent validity was demonstrated as the VDI Symptoms
dimension correlated with the balance scale and the
Physical Component Summary of the SF-12 (short
version of the generic SF-36 questionnaire). Correla-
tions with the Mental Component Summary of the
SF-12 were lower. On the other hand, the VDI HRQoL
dimension yielded strong correlations with all these
questionnaires.
Responsiveness has been studied, but changes
appear to be modest. Fifty patients, whose symptoms
improved after a mean 19 days’ follow-up, also
showed improved in their VDI scores [26], but only
slightly: effect size 0.3 (VDI symptoms) and 0.2 (VDI
HRQoL), whereas an effect size of 0.5 or more is
generally required for a change to be considered mini-
mally important [39].
The UCLA Dizziness Questionnaire (UCLA-DQ)
contains ﬁve items assessing the frequency and severity
of dizziness, the impact on everyday activity, QoL, and
fear of dizziness [5]. The level of correlation between
the ﬁve items of the UCLA-DQ was not presented in
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Table 4 Principal elements of validation of mixed questionnaires
Questionnaire VDI UCLA -DQ DFI
Author Prieto (1999) [26] Honrubia (1996) [5] Hazlett (1996) [27]
Items/dimensions 36/2 5/5 44/3
Item generation VSS,VHQ, and DHI questionnaires and
patients (n = 25) and clinicians’ interviews
(n = 8; 2/ country: France, Germany, Spain,
and UK)
Clinicians’ and patients’ interview.
Patients suffering from a vestibular
dysfunction
DHI and MPI questionnaires
Included population
(validation studies)
130 Spanish patients (67 9 years,
women: 69%) recruited by GPs (32%),
neurologists (32%), and ENT specialists
(36%). Diagnosis known for 56 patients:
peripheral vertigo (56%), central vertigo
(21%), other (23%)
343 patients (18–93 years, women:
58%). Major diagnoses: migraine
(n = 98), benign positional vertigo
(n = 83), central diseases (n = 53),
Meniere’s disease (n = 47),
psychogenic disorders (n = 35),
peripheral disorders (n = 27)
184 patients (52 16 years,
women: 64%) referred to a





VDI symptoms: feelings of dizziness and
unsteadiness common associated
symptoms (14 items)
VDI QoL: psychosocial consequences of
vertigo, dizziness or imbalance (22 items)
Frequency Severity Impact on daily
activities Impact on QoL Fear of
becoming dizzy
Symptom factors (22 items)
Obvious responses of signiﬁcant
others to the dizzy (11 items)
Activity level (11 items)
Items scaling 6-point Likert verbal scale: from 1 (all the
time) to 6 (never)
5-point Likert verbal scale 5-point Likert verbal scale
Scores VDI symptoms: from 0 (absence) to 100
(maximal);VDI HRQoL: 0 (worst) to 100
(best)
1 (best) to 5 (worst) 1 (best) to 5 (worst)
Internal consistency:
Cronbach á coefﬁcient
VDI symptoms: 0.86 VDI
HRQoL: 0.92
From 0.58 to 0.89 according to
dimensions
Reproducibility
(test–retest): r = intraclass
coefﬁcient
50 patients at a 19(6)-day interval
VDI symptoms: 0.81
VDI HRQoL: 0.87
Not evaluated Not evaluated
Structural validity Factor analysis not performed on items
but on the two VDI dimensions, which
were projected on 2 factors deﬁned a
priori: physical and psychosocial.The VDI
symptoms projects itself on the physical
factor.The VDI HRQoL projects itself on
the 2 factors
Not evaluated Factor analysis performed
separately on each of the 3
dimensions, and not on all the
items
Discriminant validity The two scores of the VDI worsen in
parallel with the balance scale score The
VDI scores worsen with the perceived
severity of the symptoms (ranging score
from 0 to 10; P < 0.001)
Signiﬁcant (P < 0.01) impact of the
frequency and the severity of the
dizziness on the 3 others items of
the questionnaire (daily activities,
QoL, and fear of dizziness).The
impact of the frequency dizziness
on the QoL and fear is
signiﬁcantly different according to
the following pathologies: BPPV,
peripheral disorders, and migraine.
The most negative impact on the
QoL is observed in the
“psychogenic” group, the weakest
in the patients with benign
paroxysmal positional vertigo
Not evaluated
Convergent validity VDI symptoms is correlated with balance
scale (r = -0.57) and PCS (r = -0.5).
Correlation values are low with MCS
(r = -0.3) and GHQ (r = 0.17) VDI HRQoL
is correlated with all the questionnaires:
balance scale (r = 0.61), PCS (r = 0.57),
MCS (r = 0.61) and GHQ (r = -0.43)
Not evaluated Not evaluated
Responsiveness During a follow-up, 50 patients felt
improved and 12 worsened using
symptom severity scale.The corresponding
change* for these patients is 0.2 for VDI
HRQoL and ranged between 0.3 and 0.5
for VDI symptoms
Not evaluated Not evaluated
Total number of patients 155 680 184
*Effect size: ratio of mean change/standard deviation of this change.
Mixed questionnaires assess both symptoms and their impact on quality of life.
BPPV, benign paroxysmal positional vertigo; DFI, Dizzy Factor Inventory; DHI, Dizziness Handicap Inventory; ENT, ear, nose, and throat; GHQ, General Health Questionnaire
(questionnaire of mental health);HRQoL,health-related quality of life;MCS,Mental Component Summary of the SF-12 generic questionnaire;MPI,Multidimensional Pain Inventory;
PCS, Physical Component Summary of the SF-12; UCLA-DQ, UCLA Dizziness Questionnaire; VDI, Vertigo, Dizziness, Imbalance Questionnaire; VHQ, Vertigo Handicap
Questionnaire;VSS,Vertigo Symptom Scale.
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the initial publication. Nevertheless, Perez et al. in a
factor analysis on data from 337 Spanish patients pre-
senting with dizziness in an ENT department [14],
produced two factors: one correlated with items on
frequency, fear of dizziness, and QoL, and the other
with items on daily severity and everyday activity. The
relationship between frequency and severity of dizzi-
ness and the other three items of the questionnaire
(everyday activity, QoL, and fear of dizziness) was
signiﬁcant (P < 0.01). The impact of frequency of diz-
ziness on the QoL and fear of dizziness scores varied
signiﬁcantly with diagnosis: the greatest impairment
was observed in psychogenic disorders, and the
weakest in benign positional vertigo. Reproducibility,
convergent validity, and responsiveness were not
tested.
The Dizzy Factor Inventory (DFI) groups 44 items
into three dimensions: symptom factors, patient’s per-
ception of other signiﬁcant responses, and activity level
[27]. The initial 88 items were reduced according to
content and factor analyses. Items with a large number
of missing data, and redundant items were eliminated,
and those with the best psychometric proﬁle (e.g., low
skewness, high variance, and midrange mean) were
retained. The internal consistency of several subscales
was lower than the recommended value of 0.7, prob-
ably resulting from the small number of items con-
stituting these subscales. Factor analysis was not
performed on all items but on each of the three empiri-
cal dimensions, raising some doubt on the dimension
structure of the items. Test–retest reproducibility, dis-
criminant and convergent validity, and responsiveness
were not tested. In general, the DFI questionnaire
appears to be pertinent, but its validation needs
checking.
Symptomatic Questionnaires (Table 5)
The Vertigo Symptom Scale (VSS) quantiﬁes the
number and frequency of long- and short-term vertigo
symptoms, autonomic sensations and anxiety arousal,
and somatization [2]. The initial version included 36
items. Factor analysis yielded a four-factor structure
with 27 items. Some scales discriminated patients
according to the cause of vertigo. Patients with spon-
taneous episodic vertigo had signiﬁcantly higher scores
on the acute attack of vertigo (VACU) dimension, indi-
cating greater impairment, than did patients with non-
rotatory vertigo (P = 0.0007). Convergent validity was
veriﬁed by the correlation between the somatization
(SOM) and autonomic symptom (AU) dimensions of
the VSS, and the anxiety scale of the Hospital Anxiety
and Depression (HAD). No signiﬁcant correlation was
observed between the VACU and Vertigo of Short
Duration dimensions, and the HAD anxiety scale. The
SOM dimension also correlated with the HAD depres-
sion scale, whereas the AU dimension did not. All
subscales of the VSS correlated moderately with the
VHQ [2,29]. The VSS is the only questionnaire for
which predictive validity has been reported. A study of
101 patients found that high AU and SOM scores at
baseline were predictive of increased handicap (VHQ)
7 months later [30]. Responsiveness data are limited
[28,32].
A Spanish version of the VSS has been reported
[31]. A factor analysis involving 172 Mexican patients,
after translation of the VSS questionnaire into Spanish,
yielded a structure similar to that of the English
version, thus reinforcing the robustness of the con-
struct validity of the VSS [31]. Similarly, the data sup-
ported the convergent validity and the internal
consistency of the Spanish VSS [31].
The European Evaluation of Vertigo (EEV) assesses
the ﬁve major symptoms of vestibular syndrome: illu-
sion of movement, duration of illusion, motion intol-
erance, neurovegetative signs, and instability [33]. This
is also the only scale presented in this review that is
based on both patient and physician ratings. In the
original validation study, the EEV items correlated to
various degrees with vertigo intensity, number of
attacks, and vertigo duration. The strongest correla-
tions were observed for the number of attacks and four
of the ﬁve EEV items (neurovegetative signs excluded)
[33]. The correlations were usually strongest after
4 weeks of follow-up, rather than at baseline, possibly
because the scores improved over time. EEV was com-
pared with the AAO-HNS questionnaire, which
assesses the functional repercussions of vertigo on a
scale from 0 to 6 [36]. At the beginning of the study,
correlations between the AAO-HNS on the one hand
and illusion duration (r = 0.21), neurovegetative signs
(r = 0.35), and instability (r = 0.23) scores on the other
were moderate. Four weeks later, the coefﬁcients were
greater. Correlations between the EEV items and the
eight dimensions of the generic SF-36 questionnaire
were also assessed. Correlations were weak at baseline,
but better for the physical than for the mental SF-36
dimension. Four weeks later, correlations, although
stronger than at the beginning of the study, remained
moderate. The EEV scale also appeared to be respon-
sive. For the 90 patients showing improvement on the
AAO-HNS scale at the 4th week of study, all the EEV
scores likewise improved, with effect sizes ranging
from 0.99 to 1.5 for the ﬁve items, and a effect size of
1.75 for the total score [33]. In comparison, in the
same patients, the effect size of the dimension scores of
the generic SF-36 questionnaire ranged between 0.15
and 0.60 [33]. This larger magnitude of change in EEV
scores is rather logical, as the questionnaire measures
precise symptoms—as is the smaller effect size in the
case of QoL questionnaires, which capture broader
concepts.
The test–retest reproducibility of the EEV has been
found to be good, except for the item concerning
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Table 5 Principal elements of validation of symptom questionnaires and of a speciﬁc Meniere’s disease questionnaire
Questionnaire VSS EEV MD-POSI
Author Yardley (1992) [2] Mégnibêto (2001) [33] Murphy (1999) [34]
Items/dimensions 27/4 5/5 16/4 + 4 single items:
Item generation Literature and patients’ interviews Cardinal symptoms of vertigo Literature and patients’ interviews
Included population
(validation studies)
127 patients (18–80 years; women:
61%) attending a neuro-otology
outpatient clinic [2]. 72% of
patients symptomatic >1 year.
Major diagnoses: spontaneous
episodic vertigo without (n = 28)
or with hearing loss and/or
tinnitus (n = 33), nonrotatory
vertigo (n = 28), positional vertigo
(n = 23), single acute episode of
vertigo (n = 12)
123 patients (53 3 years; women:
74%) with vertigo, and recruited by
ENT specialists. Patients followed
during a 4-week period in an open
label study. Length of vertigo
>12 months in 50% of patients. Major
diagnoses: BPPV (n = 37), MD (n = 34),
recurrent vertigo (n = 28), vestibular
neuritis (n = 11)
85 patients (28–87 years)
Dimensions (items for
EEV)
• Acute attack of vertigo scale
(VACU)
• Vertigo of short duration (VSH)
• Somatization scale (SOM)
• Autonomic symptom scale (AU)
Illusion of movement Duration of
illusion Motion intolerance
Neurovegetative symptoms Instability
During: effects during an attack.
Between: effects between an
attack. Daily: effect of MD on daily
living activities. Job: effect of MD
on the patient’s occupation + 4
single items: Overall, my Meniere’s
disease is . . . ; my Meniere’s
disease has changed my life . . . ; my
health is . . . ; & I expect my health
in 5 years to be . . .
Items scaling 6-point Likert verbal scale: from 0
(never) to 5 (very often, more
than once a week)
The score of each item is the average
over the last 8 days
5-point scale (0–4) 6-point scale
(0–5)
Scores 0–5 Total score: 0–20.The higher the
score, the more severe the
symptomatology
0 (none) to 5 (worse ever)
Internal consistency:
Cronbach a coefﬁcient
0.69–0.83 according to dimensions Total questionnaire: 0.92
Reproducibility
(test–retest): r = intraclass
coefﬁcient (except EEV)
44 patients at a 24-h interval
0.89–0.98
45 patients with a 7-day interval 4 of
the 5 items and the total score are
not signiﬁcantly modiﬁed (Wilcoxon)
Score of “neurovegetative symptoms”
item was improved (P = 0.027)
Not evaluated
Structural validity Factor analysis Not evaluated Item–total correlation study*
Discriminant validity Some dimensions discriminate the
patients according to their
pathology (recurrent vertigo vs.
patients with instability)
Highest correlation (from 0.4 to 0.9)
between EEV items (except
neurovegetative symptoms) and the
mean number of attacks, mainly at the
4th week of follow-up
The global composite score
(ranging from 0 to 5) increases
with the answer to the question
“overall, my MD has changed to
my life “ (r = 0.49, P < 0.0001): from
0.43 0.72 in case of answer
“little if any” to 3.02 1.20 in
case of answer “extremely”
Convergent validity Correlation of AU and SOM scales
with HAD anxiety scale: r 0.43 and
0.46, No correlation of VACU and
VSH scales with HAD anxiety
scale: r = 0.06 and 0.01.
Correlation of HAD depression
scale with SOM scale (r = 0.41),
but not with AU scale (r = 0.19).
Moderate correlation between VSS
scales and VHQ: r from 0.19 to
0.41
Correlation between EEV items and
the functional scale of AAO-HNS
(from 0 to 6), in particular at the 4th
week of follow-up: r from 0.62 to
0.81. Moderate correlation between
EEV and the 8 dimensions of the
SF-36 in particular at the 4th week of
follow-up: r between 0.3 and 0.5
Not evaluated
Responsiveness 13 patients followed after an
unilateral vestibular neurotomy.
No quantiﬁed result of the VSS
In the 90 patients who improved on
the AAO-HNS scale at the 4th week
of follow-up, all the EEV scores
improved (P < 0.001) Effect size†:
Illusion of movement (1.5), duration of
illusion (1.4), motion intolerance
(1.28), neurovegetative symptoms
0.99), instability 1.26), and total score
(1.75)
Not evaluated
Total number of patients 383 123 85
*Study of the correlations of the items compared with the whole of the questionnaire; †Effect size: ratio of mean change/standard deviation of this change.
AAO-HNS,American Academy of Otolaryngology—Head and Neck Surgery; BPPV, benign paroxysmal positional vertigo; EEV, European Evaluation ofVertigo; ENT, ear, nose, and
throat; HAD, Hospital Anxiety and Depression Scale; MD, Meniere’s disease; MD-POSI, Meniere’s Disease Patients-Oriented Severity Index; SF-36, generic QoL questionnaire;
VHQ,Vertigo Handicap Questionnaire;VSS,Vertigo Symptom Scale.
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neurovegetative signs [33]. Because the EEV was par-
tially completed by a clinician, interviewers’ reproduc-
ibility was also checked. Four ENT specialists scored
video recordings of 21 patients. Interviewer agreement
was good for total EEV score and for four of the ﬁve
items, with intraclass correlation coefﬁcients ranging
from 0.87 to 0.93. For duration of illusion, however,
the coefﬁcient was low (0.58).
The EEV questionnaires have the advantage of
assessing only the cardinal symptoms of the vestibular
syndrome. The reproducibility of the neurovegetative
signs item and the interrater reliability of the duration
of illusion item require revision. The level of agreement
between patients’ and clinicians’ assessments should
also be assessed. Lastly, it should be checked that no
strong correlation exists between the ﬁve items of the
EEV, especially between illusion of movement and
duration of illusion items.
Meniere’s Disease Patient-Oriented Severity Index
(Table 5)
Meniere’s Disease Patient-Oriented Severity Index
(MD-POSI) has four dimensions: patients’ symptoms
and functional status during attacks; patients’ symp-
toms and functional status between attacks; effect of
the disease on patients’ everyday activity; effect of the
disease on patients’ work [34,35]. From an initial
pool of 30, the number of items was reduced to 20,
with 16 items grouped into four dimensions, plus
four single items. There is limited evidence of struc-
tural validity as a simple item–total correlation was
performed, but not a factor analysis. Discriminant
validity was demonstrated by changes in the total
MD-POSI score (from 0 to 5) according to the
answers on the global item “Overall, my disease has
changed my life” (P < 0.0001). It should be noted
that the patients selected for the validation study
were not severely affected, with MD-POSI scores
usually below 2 on a scale of 0 (no impairment) to 5
(severe impairment). Moreover, 81% of the patients
answered that their health was good or excellent as
compared with others of their age, 64% that they
were satisﬁed or very satisﬁed with their Meniere’s
disease treatment, and 82% that they expected good
or excellent health in the ﬁve coming years. Repro-
ducibility, convergent validity, and responsiveness
have not been tested.
Discussion and Conclusions
Assessment of vertigo and dizziness symptoms and
QoL (or handicap) is useful. Several studies have
shown weak or no correlation between symptoms
and/or QoL (assessed by DHI, VADL, VSS) on the one
hand and objective vestibular syndrome measurements
(caloric test and posturography) on the other
[1,2,22,40]. Thus, symptom and QoL questionnaires
measure concepts that are not adequately captured by
the usual so-called objective criteria. Patient assess-
ment of symptoms and QoL is thus an added value in
assessing treatment efﬁcacy. Moreover, symptoms and
QoL, although overlapping to some extent, refer to
distinct concepts, as shown by the only moderate cor-
relation between the EEV and SF-36 questionnaires
[33]. Vertigo impact on QoL thus cannot be inferred
from symptom assessment alone. All the identiﬁed
questionnaires are self-administered (although the
EEV also contains a clinician assessment): the patient
is logically the best judge of changes in his/her symp-
toms and QoL. Estimates of the impact of vertigo on
QoL differed between patients and physicians in the
UCLA-DQ validation study [5]. It is well-established
that physicians are more inclined to deem their
patient’s pain bearable than are the patients them-
selves, and that physicians tend to underestimate the
intensity of pain, especially in diseases considered non-
severe by the medical community [4,41]. Thus, the
patient’s perspective is essential in the context of
vertigo and dizziness, requiring self-assessment of both
symptoms and of QoL, as these two measure distinct
concepts.
Critical appraisal cast doubt on the validity of some
of the 10 vertigo or dizziness questionnaires found,
and especially the DHI. The VDI questionnaire had the
best validation score (Fig. 1) being adequately devel-
oped, particularly for item generation, item reduction,
reproducibility, discriminant, and convergent validity.
The development and validation of symptom and
QoL questionnaires must follow a rigorous procedure
including item generation, item reduction, reliability,
validity, and responsiveness, as well as translation and
cultural adaptation if necessary [42–44]. It is an itera-
tive process that usually involves several hundred
patients and several studies. Fewer than 100 patients
were included in the VHQ and MD-POSI validation
studies. Moreover, the patients involved in validation
studies should be representative of those having the
disease. For the DHI and VDI validations, many
patients had chronic pathology evolving over several
years. For the UCLA-DQ, a great number of patients
had psychogenic disorders and migraine. For the DFI,
the deﬁnition of the validation population was vague.
In contrast, the population of the VSS validation study
was well-deﬁned. Validation subjects should also have
a minimum level of symptom severity and/or fre-
quency. In addition, face validity can be difﬁcult to
assess, and none of the articles analyzed dealt with this
issue. The working group, however, checked whether
items appeared relevant or not to vertigo or dizziness
patients.
Reproducibility is assessed by test–retest in stable
patients. The majority of the studies had too small
a sample for test–retest (DHI, VADL, ABC, VHQ)
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[1,21,23,25], set a too short interval (DHI, VADL,
VSS) [1,2,21], or did not used an appropriate statis-
tical test (EEV) [25,33]. Comparison of scores should
be in terms of a correlation coefﬁcient (intraclass,
kappa) [42]. An interval of at least 1–3 weeks
between test and retest [24,26,33], and a number of
patients higher [2,26,33] than 30, are probably nec-
essary [8]. Item scaling is also important for the
responsiveness of a questionnaire. Apart from the
DHI, for which the three response choices seemed
unable to detect small change, all the other question-
naires propose sufﬁciently broad answer options,
such as an analogical visual scale or a Likert-type
verbal scale. It is notable, however, that for a group
of questionnaires intended to assess changes with
treatment, few studies attempted to assess responsive-
ness adequately [26,33].
Recall period (the period to which the patients’
answers must relate) is not mentioned for all question-
naires. Some questionnaires (DHI, VADL, ABC, VHQ,
UCLA) ask for answers concerning the present time.
The recall period should not be too long [2,34],
because some patients are not able to remember symp-
toms more than a few weeks [26,33]. A recall period of
3 months (MD-POSI) or 1 year (VSS) is probably
unsuitable for many clinical or research purposes.
Depending on the concepts being assessed by the
questionnaire, the appropriate questionnaire assess-
ment times, and thus the trial duration, may differ. To
assess broad QoL impact (e.g., social functioning),
patient-perceived changes may require more time than
to evaluate changes in physical symptoms resulting
from medical treatment, for example.
Respondent burden is not mentioned in any article.
The respondent burden increases with the number of
items and when items are irrelevant to the patient. The
UCLA-DQ and EEV questionnaires, with ﬁve items
only, probably have the smallest respondent burden,
facilitating their practical use. In the UCLA-DQ,
however, the single “impact on QoL” item is not
enough for assessing the multidimensionality of
QoL.
Lastly, the present review looked at questionnaires
speciﬁc to vertigo and/or dizziness. Generic QoL ques-
tionnaires such as the SF-36, may not be sensitive
enough to detect patient changes, as they fail to
capture the speciﬁc impact of vertigo/dizziness. There
may, however, be some value in including them for
comparison across populations.
In summary, the questionnaires reviewed in this
study have shown that most of those reﬂecting handi-
cap or impact on QoL are not very speciﬁc to vertigo
or dizziness, or have validation weaknesses. The VHQ
appears to have the most pertinent content, but its
validation remains to be completed. Mixed question-
naires have the same imperfections; the VDI had the
best validation score, but its responsiveness appeared
weak. As regards symptom questionnaires, the EEV
seemed to assess the ﬁve major symptoms of vestibular
syndrome satisfactorily and to be responsive.
In evaluating a symptomatic treatment for vertigo
or dizziness in a clinical trial, it is of the greatest
importance to include self-assessment of both symp-
toms and their repercussion in terms of handicap or
QoL. Several questionnaires are thus necessary. The
short EEV questionnaire may be suitable for symptom
assessment. Regarding speciﬁc handicap or QoL ques-
tionnaires, the content of the VHQ appears relevant to
the condition, but it appears that there is no enough
psychometric evidence to support its use. A generic
questionnaire is likely to lack responsiveness.
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